Ahmedabad, Oct 16 (UNI) Zydus Cadila, one of the India's leading healthcare companies, developed 'ZYT1' anti-dyslipidemic agent.
'ZYT1' may provide an alternative to statins or be an add-on to statin therapy, Zydus sources said here today.
In preclinical studies, ZYT1 has demonstrated beneficial effect on LDL-cholesterol and triglycerides, comparable to the effects seen with statins. When combined with statins, ZYT1 exhibited a pronounced effect in lowering LDL-cholesterol and triglycerides with the added benefit of a very high margin of safety.
Dyslipidemia is a clinical condition characterised by an elevation of cholesterol or triglycerides in the bloodstream.
Over 80 per cent of patients with coronary heart disease, even those currently on medication, remain above the targeted levels for cholesterol.
''There is currently a huge need for new therapies in treating dyslipidemia patients. In ZYT1, we see an interesting possibility that can adequately bridge this gap and usher in significant improvement in meeting treatment goals.'', sources added.
UNI PVN AB BDP CS2305